David Busch

David Busch possesses extensive expertise in cell and molecular biology, with a strong focus on molecular cloning, membrane trafficking, and neurodegeneration. Experience includes a postdoctoral research fellowship at The University of Texas at Austin, where innovative approaches were developed to engineer chimeric protein constructs and investigate membrane-protein interactions. During graduate studies, David contributed to the identification of molecular targets linked to spinal cord injury, resulting in published research. Previous roles at Conforma Therapeutics and Biogen involved research and development of small molecule inhibitors for cancer therapy, contributing to an IND filing for clinical trials. Recent positions at Merck encompassed various leadership roles in pre-clinical development, highlighting a commitment to advancing therapeutic solutions. David Busch holds a PhD from The University of Texas at Austin and a B.S. in Biology from the University of California, San Diego.